Cell-therapy

Delve into the world of Cell-therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Cell-therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes
CompanyDrug

GenFleet Presents Phase Ia Data for Oral Pan‑RAS Molecular‑Glue Inhibitor GFH276 at ESMO 2026 – 41.1 % ORR in Pretreated Pancreatic Cancer Across RAS Mutation Subtypes

GenFleet Therapeutics (HKG: 2595) announced preliminary clinical data from its Phase Ia dose‑escalation study of investigational GFH276, an oral molecular‑glue Pan‑RAS inhibitor, in patients with pretreated RAS‑mutant solid tumors –…

CStone's Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

CStone’s Trispecific Antibody CS2009 Achieves Key Clinical Validation at ESMO 2026 – Simultaneous Proof of Mechanism, Safety and Concept Across 300+ Solid Tumor Patients, 100 % ORR/DCR in PD‑L1‑High First‑Line NSCLC

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Eli Lilly Presents First‑Line NSCLC Data for Next‑Generation KRAS G12C Inhibitor Olomorasib at ESMO 2026 – Durable PFS Not Reached at Nearly 21 Months with KEYTRUDA Combination

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy

CompanyDeals

BRL Medicine Raises RMB 200M in Series B Financing for CGT Development

CompanyDeals

Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies

CompanyDrug

Reforgene Medicine RM-001 Thalassemia Gene Editing

CompanyDeals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

CompanyDeals

Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development

Company

Allogene Overland Biopharm Completes State-of-the-Art AlloCAR T Facility in Shanghai

CompanyDeals

JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform

Show More